447401-91-4

Basic information

• Product Name: Ethyl 1-Ethylpyrazole-4-carboxylate
• Synonyms: Ethyl 1-Ethylpyrazole-4-carboxylate;ethyl 1-ethyl-1H-pyrazole-4-carboxylate
• CAS NO: 447401-91-4
• Molecular Formula: C8H12N2O2
• Molecular Weight: 168.19308
• Mol File: 447401-91-4.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 253.9±13.0 °C(Predicted)
• Appearance: /
• Density: 1.11±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• Solubility: Chloroform (Slightly), DMSO (Slightly)
• PKA: 0.13±0.10(Predicted)
• CAS DataBase Reference: Ethyl 1-Ethylpyrazole-4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 1-Ethylpyrazole-4-carboxylate(447401-91-4)
• EPA Substance Registry System: Ethyl 1-Ethylpyrazole-4-carboxylate(447401-91-4)

Safety Data

• Hazardous Substances Data: 447401-91-4(Hazardous Substances Data)

Usage

Description

Ethyl 1-Ethylpyrazole-4-carboxylate is an organic compound with the molecular formula C10H13NO3. It is a derivative of pyrazole, a five-membered heterocyclic compound containing two nitrogen atoms. Ethyl 1-Ethylpyrazole-4-carboxylate is characterized by its potential reactivity and utility in the synthesis of various pharmaceutical compounds.

Uses

Used in Pharmaceutical Industry:
Ethyl 1-Ethylpyrazole-4-carboxylate is used as a reactant for the preparation of N-heteroaryl benzenesulfonamides, which are known as CCR9 inhibitors. These inhibitors play a crucial role in the treatment of various diseases, particularly those related to the immune system and inflammation. By targeting the CCR9 receptor, these compounds can modulate the immune response and potentially offer therapeutic benefits in the management of autoimmune disorders and other conditions.

Upstream product

• 37622-90-5 4-ethoxycarbonylpyrazole 
• 75-03-6 ethyl iodide 

Downstream Products

• 905307-04-2 (1-ethyl-1H-pyrazole-4-yl)methanol 
• 400858-54-0 1-ethyl-1H-pyrazole-4-carboxylic acid 
• 1359029-12-1 ethyl 1-ethyl-5-{2-[4-(trifluoromethyl)phenyl]ethyl}-1H-pyrazole-4-carboxylate 
• 1359029-13-2 ethyl 1-ethyl-5-{2-[4-(trifluoromethyl)phenyl]ethenyl}-1H-pyrazole-4-carboxylate 

Relevant articles and documents

BENZODIAZEPINE DERIVATIVES FOR TREATING A RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION

Benzodiazepine derivatives of formula (I): wherein: each of R1 and R2 is independently H or halo; R3 is H, C1-C6 alkyl, -NHR8 or -OR'; either (i) a, c, and e are all bonds, with b, d and f absent; or b, d and f are all bonds, with a, c and e absent; R4 is H or a group selected from C1-C6 alkyl, C3-C6 cycloalkyl and 4- to 10-membered heterocyclyl, the group being unsubstituted or substituted; R5 is H or halo; R6 is -OR8, -NR8R9 or -R8; R7 is H or halo; each of R8 and R9 is independently H or a group selected from C1-C6 alkyl, C3-C6 cycloalkyl and 4- to 10-membered heterocyclyl, the group being unsubstituted or substituted; R' is H or C1-C6 alkyl; and one of V and W is CH and the other is N or CH; and the pharmaceutically acceptable salts thereof are inhibitors of RSV and can therefore be used to treat or prevent an RSV infection.

3-((1H-PYRAZOL-4-YL)METHYL)-6'-(PHENYL)-2H-(1,2'-BIPYRIDIN)-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS GPR139 ANTAGONISTS FOR USE IN A METHOD OF TREATMENT OF E.G. DEPRESSION

The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer's disease

SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS

The present invention relates to the pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I), as well as pharmaceutical compositions containing them, and their use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals, in particular their use in the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders.